Post

New research · Hematology
The Korean journal of internal medicine · 22h
GuidelineThe Korean journal of internal medicine · 2026

Korean expert consensus on the management of thrombotic thrombocytopenic purpura.

Seo-Yeon Ahn, Junshik Hong, Jin Seok Kim … Korean Society of Hematology Thrombosis and Hemostasis Working Party and the Korean Society on Thrombosis and Hemostasis
Read paper
HematologyGuideline
“

Korean expert consensus on the management of thrombotic thrombocytopenic purpura.

Seo-Yeon Ahn et al. · The Korean journal of internal medicine · 2026
Background

Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening thrombotic microangiopathy resulting from severe ADAMTS13 deficiency.

Purpose

By integrating international evidence with local circumstances, this document aims to provide Korean clinicians with practical, upto-date guidance to enhance the routine care of patients with TTP.

More results

Although effective treatments, such as therapeutic plasma exchange, immunosuppressive therapy with rituximab, and caplacizumab, have significantly improved survival, important challenges remain.

These include limited diagnostic capacity, barriers to the early use of novel therapies, and long-term complications.

More results

In Korea, additional difficulties persist due to the restricted availability of ADAMTS13 antibody testing, reimbursement limitations for rituximab, and the absence of caplacizumab in clinical practice.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Study
92.3%
Share of treated patients whose lymphoma shrank or cleared after treatment
Randomized Trial
60%
Cumulative mortality was 60% with beta-glucan, reduced from 100% in untreated fish.
Cohort Study
HR 2.59
sudden kidney damage meant over twice the risk of death for CAR-T recipients
Study
30%
About 30% of peptides from multiple myeloma cell lines stimulated CD8+ T-cell responses.
AI / Informatics
C-index = 96.0%
The model accurately predicted when initial leukemia treatment would not work
Cohort Study
97.30%
The AI model correctly identified aplastic anemia or myelodysplastic syndromes 97.30% of the time.
Cohort Study
55.9% vs. 68.1%
Diabetic patients had lower major molecular response at 12 months (55.9% vs 68.1%).
Cohort Study
OR 3.8
Each additional low lab value associated with 3.8 times higher odds of Multisystem Inflammatory Syndrome in Children.